drugset / Trial / NCT06003270

Biological Effects of Quercetin in COPD Phase II

NCT06003270

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receiving quercetin 1000 mg/day, 8 patients receiving 500 mg/day and 4 subjects receive placebo.

Timeline

Start
2023-11-01
Primary completion
2025-02-15
Completion
2025-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quercetin Small molecule 500 mg Oral
Comparator Quercetin Small molecule 1000 mg Oral